ArticlePloS one2025
Altered carnitine-acylcarnitine profiles in levothyroxine-treated congenital hypothyroid patients with fatigue: An LC-MS/MS-based study from Bangladesh.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital hypothyroidism (CH), characterized by insufficient thyroid hormone production at birth, is frequently associated with fatigue, particularly in cases with delayed diagnosis. This study employed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to profile carnitine and acylcarnitines in late-diagnosed congenital hypothyroid patients receiving levothyroxine (LT4) therapy, with the aim of identifying metabolic alterations that may be associated with fatigue symptoms. A total of 56 late-diagnosed congenital hypothyroid patients and 107 age-, sex-, and BMI-matched healthy controls were enrolled. Blood samples were collected in EDTA tubes and as dried blood spots (DBS) on Whatman® 903 filter paper. LC-MS/MS was used to quantify free carnitine and 28 acylcarnitines, and plasma triglyceride (TG) levels were measured using a biochemical analyzer. Compared to healthy controls, congenital hypothyroid patients showed higher mean (±SD) concentrations of free carnitine (45.38 ± 12.61 vs. 41.54 ± 9.85 µmol/L; P = 0.049), total carnitines (67.33 ± 18.27 vs. 62.51 ± 14.13 µmol/L), and total acylcarnitines (21.95 ± 7.66 vs. 20.96 ± 5.61 µmol/L), although only free carnitine levels were statistically significant. Long-chain acylcarnitines were significantly lower in congenital hypothyroid patients (2.67 ± 0.87 µmol/L) compared to controls (3.15 ± 0.93 µmol/L; P = 0.0014). The β-oxidation ratio C0/(C16 + C18), a proxy for Carnitine Palmitoyltransferase I (CPT-I) activity, was significantly elevated in patients compared to healthy controls (34.55 ± 14.88 vs. 25.73 ± 6.87; P < 0.0001). Plasma TG levels were also significantly higher in patients (88.92 ± 59.54 mg/dL) than in controls (58.33 ± 15.79 mg/dL; P = 0.02). Metabolic profiling in congenital hypothyroid patients revealed impaired long-chain fatty acid oxidation and elevated triglyceride levels. These metabolic changes may contribute to fatigue symptoms and are potentially associated with reduced CPT-I activity, which is essential for mitochondrial β-oxidation. Additionally, mutations in the TPO and TSHR genes identified within this cohort may be linked to the observed metabolic alterations. Collectively, these findings suggest a possible interplay between genetic variants, disrupted lipid metabolism, and clinical features of congenital hypothyroidism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.